Tag Archives: Sophiris Bio

August, 2018

• 30 August

  Sophiris Bio Updates on Phase 2b Trial of Investigational Topsalysin in Prostate Cancer

  

  SAN DIEGO and VANCOUVER, British Columbia, Aug. 29, 2018 /PRNewswire/ — Sophiris Bio Inc. (NASDAQ : SPHS ) (the “Company” or “Sophiris”), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced the conclusion of the …

  Share

  • Facebook
  • Twitter
  • LinkedIn

November, 2015

• 11 November

  Sophiris’ Prostate Drug Meets Primary Endpoint in Late-Stage Study

  

  SAN DIEGO and VANCOUVER, British Columbia, Nov. 10, 2015 /PRNewswire/ — Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced final results from its Phase 3 “PLUS-1” study of PRX302 as a treatment for lower urinary tract symptoms …

  Share

  • Facebook
  • Twitter
  • LinkedIn